Teva could merge with Mylan or Valeant, Bloomberg reports

If Teva Pharmaceutical Industries (TEVA) can’t restore value on its own and doesn’t soon find a new CEO, a merger with generic drug makers Mylan (MYL) or Valeant Pharmaceuticals International. (VRX) appears likely, reports Bloomberg.